Presumed sertraline maculopathy.
OBJECTIVE
To report a unique case of a woman who developed simultaneous bilateral maculopathy presumed to result from intake of sertraline hydrochloride, a serotonin reuptake inhibitor.


METHODS
Full clinical ocular examination, color vision testing, automated static perimetry, electroretinography, electrooculography and fundus fluorescein angiography were performed. Living members of her family were also examined.


RESULTS
The patient had normal electroretinography and electrooculography results. Automated static perimetry showed generalized reduction of sensitivity and central scotomas. Macular lesions resolved 6 months after discontinuation of sertraline, however, during twenty months of follow-up her visual acuity and abnormalities in other psychophysical tests did not improve.


CONCLUSIONS
Patients started on sertraline should be informed of the potential risk of developing maculopathy, and they should be examined regularly to detect possible early alterations.
Sener
E C
EC
Department of Ophthalmology, Hacettepe University School of Medicine, Ankara, Turkey.
Kiratli
H
H
D004585:Electrooculography; D004596:Electroretinography; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008266:Macula Lutea / Q000187:drug effects* / Q000473:pathology; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*; D020280:Sertraline / Q000009:adverse effects*; D014792:Visual Acuity
D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline